Edgewise Therapeutics (EWTX) Net Cash Flow (2020 - 2026)

Edgewise Therapeutics has reported Net Cash Flow over the past 7 years, most recently at -$27.9 million for Q1 2026.

  • Quarterly results put Net Cash Flow at -$27.9 million for Q1 2026, down 438.43% from a year ago — trailing twelve months through Mar 2026 was -$16.7 million (down 185.01% YoY), and the annual figure for FY2025 was $19.5 million, up 143.85%.
  • Net Cash Flow reached -$27.9 million in Q1 2026 per EWTX's latest filing, down from $15.1 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $91.4 million in Q3 2022 and bottomed at -$87.8 million in Q4 2022.
  • Median Net Cash Flow over the past 5 years was $1.3 million (2024), compared with a mean of $1.0 million.
  • The largest annual shift saw Net Cash Flow crashed 1856.84% in 2022 before it soared 582.32% in 2025.
  • Over 5 years, Net Cash Flow stood at -$87.8 million in 2022, then skyrocketed by 160.56% to $53.1 million in 2023, then tumbled by 105.91% to -$3.1 million in 2024, then skyrocketed by 582.32% to $15.1 million in 2025, then crashed by 284.46% to -$27.9 million in 2026.
  • Business Quant data shows Net Cash Flow for EWTX at -$27.9 million in Q1 2026, $15.1 million in Q4 2025, and $2.6 million in Q3 2025.